Fineline Cube

Follow:
14446 Articles
Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion
Others

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies
CompanyDeals

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Novo Nordisk's Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe
CompanyDrug

Novo Nordisk’s Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1
CompanyDeals

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Alexion's Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca's Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle
CompanyDrug

Alexion’s Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca’s Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle

Novartis' Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology
CompanyDrug

Novartis’ Cosentyx Wins Positive CHMP Opinion for Polymyalgia Rheumatica – IL‑17A Blockade Poised to Enter Steroid-Dependent Rheumatology

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer
CompanyDrug

Eli Lilly Wins Full FDA Approval for Inluriyo–Verzenio Combination – Oral Regimen Doubles Median Progression-Free Survival in ESR1-Mutated Metastatic Breast Cancer

FDA Accepts Alexion's BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+
CompanyDrug

FDA Accepts Alexion’s BLA for Efzimfotase Alfa With Priority Review – Potential Twice‑Monthly Enzyme Replacement Therapy for Hypophosphatasia (HPP) Patients Aged 2+

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC
CompanyDrug

Nuvation Bio Secures FDA sNDA Approval for IBTROZI® (Taletrectinib) – Updated Label Reports Longest Median DOR Among Approved ROS1 TKIs in TKI‑Naïve ROS1‑Positive NSCLC

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030